Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Soleno Therapeutics Receives Breakthrough Therapy Designation From FDA For DCCR Extended-Release Tablets in Prader-Willi Syndrome

Author: Benzinga Newsdesk | April 29, 2024 08:02am

First Ever Breakthrough Designation for a Drug Being Developed for PWS

Designation is Based on Data from the Phase 3 Program for DCCR

Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid-2024

Posted In: SLNO